Patients with hepatocellular carcinoma extrahepatic metastases can benefit from hepatic arterial infusion chemotherapy combined with lenvatinib plus programmed death-1 inhibitorsRenguo Guan, Rongping Guo, Nan Zhang et al.|International Journal of Surgery|2024Cited by 36
Nomograms for predicting the recurrence probability and recurrence-free survival in patients with hepatocellular carcinoma after conversion hepatectomy based on hepatic arterial infusion chemotherapy: a multicenter, retrospective studyMin Deng, Rongping Guo, Qiucheng Lei et al.|International Journal of Surgery|2023Cited by 15
Hepatic Arterial Infusion Chemotherapy vs Transcatheter Arterial Chemoembolization as Adjuvant Therapy Following Surgery for MVI-Positive Hepatocellular Carcinoma: A Multicenter Propensity Score Matching AnalysisRong Guo, Lianghe Lu, Jie Mei et al.|Journal of Hepatocellular Carcinoma|2024Cited by 10
Comparative efficacy of PD-1 inhibitors plus lenvatinib and regorafenib after lenvatinib failure for advanced hepatocellular carcinoma: a real-world studyRenguo Guan, Rong Guo, Jie Mei et al.|Hepatology International|2023Cited by 6
Prognosis prediction of α-FAtE score for locoregional immunotherapy in hepatocellular carcinomaZehao Zheng, Rongping Guo, Renguo Guan et al.|Frontiers in Immunology|2025Cited by 4